Hany Massarany Net Worth

The estimated Net Worth of Hany Massarany is at least $3.84 Million dollars as of 28 June 2024. Hany Massarany owns over 4,737 units of Biodesix Inc stock worth over $66,035 and over the last 13 years Hany sold BDSX stock worth over $3,771,374.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Hany Massarany BDSX stock SEC Form 4 insiders trading

Hany has made over 83 trades of the Biodesix Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Hany exercised 4,737 units of BDSX stock worth $8,479 on 28 June 2024.

The largest trade Hany's ever made was exercising 145,833 units of Biodesix Inc stock on 31 March 2023 worth over $261,041. On average, Hany trades about 11,312 units every 43 days since 2012. As of 28 June 2024 Hany still owns at least 36,891 units of Biodesix Inc stock.

You can see the complete history of Hany Massarany stock trades at the bottom of the page.

What's Hany Massarany's mailing address?

Hany's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.

Insiders trading at Biodesix Inc

Over the last 4 years, insiders at Biodesix Inc have traded over $0 worth of Biodesix Inc stock and bought 32,782,268 units worth $58,800,766 . The most active insiders traders include Jack W Schuler, Lawrence T. Jr Kennedy, and Matthew Strobeck. On average, Biodesix Inc executives and independent directors trade stock every 12 days with the average trade being worth of $567,788. The most recent stock trade was executed by Chris Vazquez on 8 August 2024, trading 602 units of BDSX stock currently worth $1,078.

What does Biodesix Inc do?

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Complete history of Hany Massarany stock trades at Accelerate Diagnostics Inc, GenMark Diagnostics Inc, and Biodesix Inc

Biodesix Inc executives and stock owners

Biodesix Inc executives and other stock owners filed with the SEC include:

• Scott Hutton,
  Pres, CEO & Director
• Robin Harper Cowie,
  CFO, Sec. & Treasurer
• Kieran O'Kane,
  Chief Commercial Officer
• Dr. Robert W. Georgantas III, Ph.D.,
  Chief Scientific Officer
• Dr. Heinrich Röder,
  Founder & CTO
• Dr. Gary Anthony Pestano Ph.D.,
  Chief Devel. Officer
• Dr. Paul J. Beresford,
  Chief Bus. Officer
• Matt Stauffer,
  VP of Sales
• Jeffrey A. Bojar,
  VP of Legal and Regulatory Affairs
• Ryan H. Siurek,
  Chief Accounting Officer
• Robert E. Cawthorn,
  Founder & Director Emeritus
• Dr. Heinrich Röder,
  Founder & CTO
• John Patience,
  
• Matthew Strobeck,
  
• Charles M Watts,
  
• Gary Anthony Pestano,
  Chief Development Officer
• Kieran O'kane,
  Chief Commercial Officer
• Scott Hutton,
  President & CEO
• Ryan H Siurek,
  Chief Accounting Officer
• Jon Faiz Kayyem,
  
• Hany Massarany,
  
• Jean M. Franchi,
  
• Jack W Schuler,
  
• Robin Harper Cowie,
  CFO, Sec'y & Treasurer
• Robert William Iii Georgantas,
  Chief Scientific Officer
• Lawrence T. Jr Kennedy,
  
• Chris Vazquez,
  Chief Accounting Officer